Physician profile
John Caras
NPI 1639157837
$5,430.14
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,088 · 2020: $844 · 2021: $497.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $3,128.39 | 2019-2020 | |
| Novo Nordisk INC | $1,178.93 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $395.52 | 2019-2021 | |
| Medtronic Minimed, INC. | $216.96 | 2019-2020 | |
| Abbott Laboratories | $142.22 | 2020-2021 | |
| Ibsa Pharma INC. | $65.64 | 2019-2021 | |
| Lilly USA, LLC | $54.59 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.92 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $37.80 | 2020-2021 | |
| Insulet Corporation | $37.40 | 2019 | |
| Horizon Therapeutics Plc | $22.63 | 2021 | |
| Dexcom, INC. | $18.28 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.09 | 2020 | |
| Amarin Pharma, INC. | $14.05 | 2019 | |
| Sun Pharmaceutical Industries INC. | $12.84 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.70 | 2019 | |
| Esperion Therapeutics, INC. | $12.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.89 | 2019 | |
| Tandem Diabetes Care, INC. | $11.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Caras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.